Cardiovascular CDMOs

Matrix Pharma Corp. Private Ltd. (CDMO BU)

India

Matrix Pharma Corp. Private Ltd. (CDMO BU) is a leading Indian integrated API manufacturer and CDMO specializing in active pharmaceutical ingredients with particular expertise in complex molecules, high-potency drugs, and APIs across therapeutic areas including antiretrovirals, antivirals, antihypertensives, cardiovascular, and CNS therapies. The company operates six state-of-the-art manufacturing facilities with over 3,850 kL installed capacity, including dedicated units for ARVs, peptides, and iron complexes. FDA-registered with 5 FEI numbers and extensive inspection history (25 inspections: 9 NAI, 15 VAI, 1 OAI). Recently inaugurated an oncology manufacturing facility in Vizag.

Metrochem API Pvt Ltd

India

Metrochem API Pvt Ltd is a vertically integrated Indian pharmaceutical API manufacturer based in Hyderabad, approved by USFDA (EIR), WHO-GMP, COEFPRIS, KFDA, and ISO 9001. The company has over 300 API and pellet registrations across various countries. Their manufacturing facility spans 50,000 sqm with 700kl reaction volume. Metrochem has received China NMPA approval for Teneligliptin hydrobromide and manufactures APIs such as Rabeprazole Sodium and Efinaconazole.

Midas Pharma GmbH

Germany

Midas Pharma GmbH is a German pharmaceutical company headquartered in Ingelheim, providing end-to-end services across the pharmaceutical value chain including contract development, contract manufacturing, supply chain management, regulatory affairs, quality and compliance, IP services, and reference product sourcing. The company has a particular specialization in Hot Melt Extrusion (HME) technology for high potent drugs with over 10 years of hands-on experience. Midas has FDA and EU GMP-certified manufacturing sites and offers contract manufacturing of finished dosage forms, intermediates, and drug substances. They also have a biosimilar pipeline including Ranibizumab.

Minakem (Minafin Group)

Belgium

Minakem, part of the Minafin Group, is a pharmaceutical CDMO with over 60 years of legacy in API development and manufacturing, headquartered in Belgium with production facilities in France, Belgium, and Canada. The company specializes in custom small molecule API and HPAPI development and manufacturing, with over 500m3 total reactor capacity. Minakem has 5 FDA-registered facilities performing API manufacture and analysis, has completed 19 FDA inspections (7 NAI, 12 VAI, 0 OAI), and recently expanded its API portfolio with 5 additional DMF holdings. The company also offers human and animal health APIs including Estradiol, Trenbolone, Fluvastatin, and Fulvestrant with an innovative Gen2 process reducing CO2 footprint.

Morepen Laboratories Limited

India

Morepen Laboratories Limited is an Indian pharmaceutical company with 40+ years of expertise in API and formulation manufacturing. The company has recently secured an INR 825 crore (approx. USD 100M) multi-year global CDMO mandate, marking a significant expansion into contract manufacturing. Morepen operates a scientifically integrated complex in Baddi with 10 dedicated manufacturing plants. The company exports to 80+ countries and holds FDA, WHO GMP, and EU GMP certifications. Known for the consumer brand Dr. Morepen (home health devices).

Numaferm GmbH

Germany

Numaferm GmbH is a German biotech company specializing in the biochemical production of peptides and proteins using its proprietary Numaswitch and Numatech expression platforms. The company offers contract development and manufacturing services from discovery through commercial/GMP supply, partnering with established CMOs for large-scale production. Numaferm has completed over 200 successful peptide projects and is ISO 9001:2015 certified.

Opocrin SpA

Italy

Opocrin SpA is an Italian pharmaceutical company with nearly 60 years of experience, recognized as a global leader in the research, production, and commercialization of active pharmaceutical ingredients and complex molecules, with a specialization in heparins and their derivatives. The company also produces glycosaminoglycans, iron complexes, and pulmonary surfactants.

Orchev Pharma Pvt Ltd

India

Orchev Pharma Pvt. Ltd., established in 1989 in Gujarat, India, is a manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates specializing in Ranitidine HCl, Famotidine, Telmisartan, and Levetiracetam. The facility is US-FDA, EU-GMP (AEMPS), WHO-GMP, KFDA, and COFEPRIS certified. USFDA inspection in 2018 was cleared with zero 483 observations.

Pharmicell Chemical

South Korea

Pharmicell Co., Ltd. is a South Korean biopharmaceutical company operating both chemical (API) and biologics (stem cell therapy) divisions, with CDMO services. The Chemical Business Unit in Ulsan (Onsan) manufactures oligonucleosides, pharmaceutical PEGs, and industrial advanced materials. The Bio division developed the world's first approved stem cell therapy (Hearticellgram AMI for cardiac repair) and provides CDMO services for advanced cell therapies with GMP facilities including Grade B/C clean rooms, virus testing labs, and microorganism testing labs. The company holds ISO 9001, ISO 14001 certifications and reported record revenue of 114 billion KRW in 2025. Pharmicell is expanding CDMO operations for regenerative medicine with capability to handle 7 cell types.

QuVA Pharma

United States

QuVA Pharma is a US-based FDA-registered 503B outsourcing facility specializing in sterile compounding of ready-to-administer injectable medicines for hospitals. They serve over 3,000 US hospitals and operate multiple manufacturing and forward distribution centers. They also offer AI-powered analytics (Quva BrightStream) for health-system pharmacy data insights. Notable regulatory history includes multiple OAI inspections and Class I/II recalls.

REMEDICA LTD

Cyprus

REMEDICA is a Cyprus-based pharmaceutical manufacturer that has been operating for over four decades, distributing products in more than 160 countries. They manufacture generics across multiple therapeutic areas and dosage forms (solid oral dose, liquids, semi-solids, sterile injectables) and offer contract manufacturing (CMO/CDMO) services. They have long-standing relationships with NGOs (UNICEF, WHO, UNRWA). They focus on B2B partnerships, own-brand commercialization (Cyprus, Eastern EU, Asia, Middle East, Africa, LATAM), and NGO supply.

Softgel Healthcare Pvt Ltd

India

Softgel Healthcare Pvt Ltd is an Indian CDMO with over 18 years of expertise in formulating, developing, and manufacturing soft gelatin capsules. Operating USFDA and EU-GMP approved facilities, the company serves over 100 partners in 60+ countries. Key products include Enzalutamide, Cyclosporine, Tafamidis, Nintedanib, and other complex softgel formulations. The company was acquired by Everstone Capital.

Synergene Active Ingredients Private Limited

India

Synergene Active Ingredients is a fast-growing Indian API manufacturer incorporated in 2006, with 40 years of industrial experience and 800+ employees. The company manufactures 30+ APIs serving 300+ customers in 50+ countries. Synergene operates four manufacturing units in Hyderabad and Visakhapatnam with combined production capacity of 800+ KL (plus 700 KL under installation). The company has CEPs from EDQM, US DMFs, Japanese DMFs, ANVISA CBPF, and WHO GMP certifications. Synergene also produces specialty chemicals for skincare, sun care, and haircare applications.

Syn-Tech Chem & Pharm Co. Ltd

Taiwan

Syn-Tech Chem & Pharm Co. Ltd is a Taiwanese API manufacturer established over 30 years ago, providing good quality APIs to customers worldwide including USA, Japan, Korea, and Europe. The company has passed multiple regulatory audits and holds PMDA, US FDA, KFDA, and TFDA approvals. Syn-Tech is expanding its CDMO capabilities and manufactures APIs such as guanfacine HCl and crotamiton. The company won the 2003 National Biotechnology and Medical Quality Award in Taiwan.

TITAN PHARMAPLUS PVT. LTD

India

Titan Pharmaplus Pvt. Ltd. is an Indian pharmaceutical API manufacturer and CDMO committed to innovation, quality, and sustainability. The company produces a wide range of small molecule APIs including Apixaban, Dapagliflozin, Acyclovir, Dexlansoprazole, and controlled substances, with state-of-the-art cGMP facilities and advanced chemical synthesis capabilities including high-pressure hydrogenation, Grignard reactions, and asymmetric oxidation.

Trifarma S.p.A.

Italy

Trifarma S.p.A. is an international and independent Italian group dedicated to developing, manufacturing, and supplying high-quality Active Pharmaceutical Ingredients (APIs) to the global pharmaceutical industry. The company has R&D laboratories for synthetic organic chemistry process development at lab and pilot scale, with rapid lab-to-industrial scale development. API portfolio covers cardiovascular, anti-infective, nervous system, dermatological/ophthalmic, steroids, and musculoskeletal categories.

Vihita Chem (P) Ltd

India

Vihita Chem Private Limited is an Indian API and intermediates manufacturer established in 1990 in Ankleshwar, Gujarat. The company manufactures APIs (Donepezil, Valsartan, Losartan, Atorvastatin, Pinaverium Bromide), API intermediates, fragrance intermediates, specialty chemicals, and customized products. Three manufacturing facilities in Ankleshwar GIDC, with additional land acquired at Dahej and Jhagadia for Units 3 and 4. ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 certified. FEI number 3004562353. R&D recognized by DSIR, Ministry of Science and Technology, Government of India. 200+ employees, 100+ products. Building EU-GMP facility in Unit-2.

Cambridge Isotope Laboratories, Inc.

France

Cambridge Isotope Laboratories (CIL) is a manufacturer of stable isotope-labeled compounds used as reference standards, internal standards, and tracers in pharmaceutical analysis and research. The company is FDA-registered for API manufacture of labeled compounds and supplies the pharmaceutical industry with analytical reference materials.

Caplin Point Laboratories is a fully integrated Indian pharmaceutical company with a dominant presence in Latin America and Francophone Africa, and a growing presence in the US and EU. Through its subsidiary Caplin Steriles, the company manufactures sterile injectables, ophthalmic products, pre-mix bags, and pre-filled syringes, with 46 FDA-approved products.

Cenra Pharma (formerly CCPC, China Chemical & Pharmaceutical Co.) is a Taiwanese pharmaceutical company established in 1952 that develops and manufactures APIs and generic drugs, also providing CMO/CDMO services. The company has FDA and PMDA facility approvals, PIC/S GMP compliance, and offers services from API selection through formulation development and commercial manufacturing. Cenra specializes in high-potency drugs including immunosuppressants and oncology drugs, with dedicated production lines for penicillins, cephalosporins, carbapenems, and immunosuppressants.

DongBang Future Tech & Life Co., Ltd

South Korea

DongBang Future Tech & Life Co., Ltd is a South Korean pharmaceutical company founded in 1990 that operates as a CDMO for chemical APIs and finished drugs. The company specializes in HPAPI, PROTAC, and hybrid small molecule development, with 35+ active CMC and CDMO projects for global pharma and biotech companies.

Finecure Pharmaceuticals Limited

India

Finecure Pharmaceuticals Limited is an Indian pharmaceutical formulation company with WHO-GMP certified manufacturing facilities producing oral dosage forms and injections. The company focuses on niche therapeutic segments including cardiovascular, anti-retroviral, neurology, and anti-infectives, with a presence across India and export markets.

GENSENTA

Turkey

Gensenta (formerly Mustafa Nevzat Ilac, acquired by Amgen in 2012 and sold to Eczacibasi in 2020) is a vertically integrated Turkish pharmaceutical company with two manufacturing facilities in Yenibosna and Sekerpinar, Turkey. The company manufactures both drug products and raw materials (APIs), and has been recognized in the sterile injectable CDMO market. Gensenta is listed as part of the Eczacibasi group and produces pharmaceuticals including caspofungin.

Gruppo Farma Impresa S.r.l.

Italy

Gruppo Farma Impresa is an Italian contract manufacturer specializing in medical devices based on substances, food supplements, and dermocosmetics, offering private label production (conto terzi) and out-licensing of over 1,000 ready-to-market products. The company provides formulation development, R&D with over 200 new formulations annually, regulatory affairs support, and clinical trial services across multiple therapeutic areas.

Huazhong Pharmaceutical Co., Ltd. (HPC) is a Chinese pharmaceutical company established in 1995, manufacturing APIs, intermediates, and finished dosage forms including tablets. The company has GMP manufacturing sites with capabilities in both biological transformations and chemical synthesis, producing products such as albendazole, isoniazid, paracetamol, and nifedipine tablets.

Hubei Enoray Biopharmaceutical Co., Ltd. is a Chinese high-tech biopharmaceutical company specializing in R&D, production, sales, and export of heparin, graded low molecular weight heparin APIs, and new antithrombotic drugs. The company holds EU GMP, Russian GMP, and US FDA approvals for its heparin and enoxaparin sodium production.

IDI Integratori Dietetici Italiani srl is an Italian pharmaceutical company engaged in the development and manufacturing of pharmaceutical products, dietary supplements, and medical devices. The company has FDA-registered facilities and produces a range of products including tablets, creams, oral solutions, and injectable formulations across multiple therapeutic areas.

JEWIM Pharmaceutical (Shandong) Co., Ltd. is a Chinese pharmaceutical company in transformation, focusing on innovative drugs and complex drug delivery systems including inhalation products, nasal sprays, and long-acting injectable microspheres. The company is an established CDMO/CMO partner for multinational pharma companies including Johnson & Johnson (Xian Janssen), Kenvue, and Bayer, with quality systems certified by US FDA and Australian TGA. Products are exported to over 80 countries.

Jubilant HollisterStier CMO

Canada

Jubilant HollisterStier CMO (subsidiary of Jubilant Pharma) specializes in sterile fill-finish, lyophilization, injectables, ophthalmics, otics, topicals, and liquids for pharmaceutical and biopharmaceutical clients. End-to-end services from process development to inspection and packaging. Facilities in Spokane, WA and Montreal, QC. Won AWB Manufacturer of the Year 2024 and Manufacturing Excellence Award 2025. Largest manufacturer by employees in Spokane area. 92% repeat customer rate. FDA registered with 4 FEI numbers, 28 inspections (6 NAI, 18 VAI, 4 OAI -- elevated regulatory risk).

Labcorp (incl. Labcorp Drug Development/Covance)

United States

Labcorp (including Labcorp Drug Development, formerly Covance) is one of the world's largest contract research organizations (CROs). They provide comprehensive drug development services including nonclinical development (toxicology, pharmacology, metabolism), central laboratory services (bioanalytical, biomarkers, genomics, companion diagnostics), and commercialization services. Labcorp supported 76% of all FDA-approved drugs in 2024. They operate across 100+ countries with services spanning from drug discovery to post-approval. While they offer CMC consulting services, their core business is contract research, not contract drug manufacturing.

Lupin Limited (Lupin Manufacturing Solutions)

Brazil

Lupin Manufacturing Solutions (LMS) is the CDMO arm of Lupin Limited, one of India's largest pharmaceutical companies. LMS offers integrated CDMO services spanning API manufacturing, formulation development, and finished dosage form production. They operate 16 FDA-registered facilities with 512 FDA-approved products. They have recently expanded into oncology with a dedicated block at Vizag, India, and formed a strategic alliance with PolyPeptide for peptide supply chain scaling. Their extensive regulatory track record includes FDA, WHO, and multiple international approvals.

Murli Krishna Pharma Pvt Ltd

India

Duplicate entry for Murli Krishna Pharma Private Ltd. (mkppl.com) - same company, same website domain. Indian pharmaceutical CDMO specializing in PFI and FDF products with CRAMS services.

Northeast Pharmaceutical Group (NEPG) is a large-scale comprehensive pharmaceutical enterprise in Shenyang, China, under Fangda Group. The company operates three major business segments: chemical synthetic API and bio-fermentation API, western medicinal preparations and micro-ecological preparations, and medical business distribution. NEPG is China's first Vitamin C producer and the inventor of the two-step fermentation technology for VC production, with the world's largest Piracetam production capacity.

Olpha (formerly Olainfarm JSC) is the leading pharmaceutical manufacturer in Latvia with over 50 years of experience and approximately 850 employees. The company produces finished dosage forms, active pharmaceutical ingredients, and intermediates across 10 therapeutic groups with a portfolio of more than 60 drug forms and 25 APIs. Olpha offers contract manufacturing and pharmaceutical co-development services, and exports to more than 60 markets. The company recently rebranded and aims to become a European top 10 pharmaceutical company.

Parexel International (MA) Corporation

Argentina

Parexel is a global contract research organization (CRO) providing clinical trial management, regulatory consulting, and biopharmaceutical development services. With over 24,000 professionals and 50+ clinical sites across five continents, the company offers Phase I-IV clinical trial services, CMC regulatory strategy, and real-world evidence generation. Parexel is primarily a CRO, not a drug manufacturer.

PharmIdea is a Latvian CDMO located in Olaine, Latvia, specializing in sterile drug development, commercial production, and worldwide supply of pharmaceutical products. The company focuses on sterile drugs in vials, offering contract manufacturing services including product development. PharmIdea has completed CTDs for out-licensing and provides contract manufacturing of sterile injectables such as Levosimendan concentrate for solution for infusion (small batch), Caspofungin, and Carbetocin. The company has partnered with Lidds for manufacturing NZ-TLR9 formulation against solid tumors.

Recordati is an Italian pharmaceutical company with both a proprietary product business (rare diseases, specialty/primary care) and a fine chemicals/CDMO division. Recordati Fine Chemicals (also known as Recordati Industria Chimica e Farmaceutica) provides contract API manufacturing. They have FDA-registered facilities, 26 approved products across multiple dosage forms, and significant industrial operations. The fine chemicals division offers API development and manufacturing services to third-party pharmaceutical companies.

DUPLICATE ENTRY: This is the same company as Sri Krishna Pharmaceuticals Ltd (companyId: 12028a28). SKPL was established in 1974 and specializes in bulk manufacture of APIs, DC granules, and finished dosage forms. See primary entry for full profile.

DUPLICATE ENTRY: This is the same company as Sri Krishna Pharmaceuticals Ltd (companyId: 12028a28). SKPL was established in 1974 and specializes in bulk manufacture of APIs, DC granules, and finished dosage forms. See primary entry for full profile.

ST Pharm is a South Korean global API CDMO company founded in 1983, specializing in small molecule APIs, oligonucleotide therapeutics (ASO, siRNA, aptamers), and mRNA-LNP manufacturing. The company operates cGMP manufacturing facilities in South Korea and has a CRO subsidiary (AnaPath) in Switzerland and Spain for preclinical pathology services.

Wanbang Biopharmaceuticals is a Chinese pharmaceutical manufacturer based in Xuzhou, Jiangsu province, specializing in the development, manufacture, and sale of pharmaceutical products. The company has FDA registration and produces products including capsules and APIs such as Febuxostat and Apixaban.

Zhejiang Hisoar Pharmaceutical Co., Ltd. (stock code 002099, Shenzhen Exchange), founded in 1966 and headquartered in Taizhou, Zhejiang, China, is a diversified pharmaceutical and chemical company with ~3,000 employees and 426 R&D personnel. Their pharmaceutical division produces specialty APIs, intermediates, formulations, and fine chemicals -- specifically antibiotics (penem/carbapenem series, clindamycin series), cardiovascular agents, and anti-diabetic APIs. Over 70% of products are exported. They also have a major dye/pigment business segment (~70% global market share in Reactive Blue KN-R). The company has 3 FDA-registered FEI numbers for API manufacture, 7 FDA inspections (4 NAI, 3 VAI, 0 OAI), 2 FDA-approved products (capsule, tablet), 40+ invention patents, and partnerships with Boehringer Ingelheim, Merck, Sanofi, Novartis, GSK, and others. Classified as API manufacturer because the core pharma business is own-brand API and intermediate production with limited CDMO positioning, though PharmaSource lists them under CMO/CDMO.

Cayman Pharma s.r.o. is a Czech pharmaceutical manufacturer specializing in cGMP prostaglandin Active Pharmaceutical Ingredients (APIs) for ophthalmology and vascular applications. The company owns a patented route to the prostaglandin core structure developed at its headquarters near Prague, and produces APIs including Latanoprost, Travoprost, Bimatoprost, Tafluprost, and Epoprostenol. cGMP compliance is continuously verified by Czech NCAs (SUKL, USKVBL) and the US FDA.

Chemport Inc. is a South Korean pharmaceutical company founded in 2008 that manufactures APIs, particularly EPA ethyl ester (Icosapent Ethyl) used in cardiovascular drugs like Vascepa. The company holds US cGMP and Korean GMP certifications for API manufacturing, with FDA registration and a clean inspection record of 3 NAI outcomes.

Chongqing Huapont Shengchem Pharmaceutical Co., Ltd., founded in 1994, is a subsidiary of listed company Huapont Life Sciences. The company provides integrated R&D, production, and CDMO services for APIs and intermediates with 30+ years of experience, 700m3 reaction volume, 100+ R&D products, and registrations across US, EU, Japan, Korea, and China.

Formosa Laboratories is a Taiwan-based CDMO specializing in custom synthesis and contract manufacturing of active pharmaceutical ingredients (APIs) for the global pharmaceutical industry. The company provides services from process development through commercial-scale API manufacturing, with FDA-registered facilities.

Hangzhou FST Pharmaceutical Co., Ltd., established in 2001, is a Chinese national high-tech enterprise primarily engaged in the R&D and production of APIs and pharmaceutical intermediates. The company focuses on antitumor (tinib series), cardiovascular, antihistamine, antipsychotic, and antiviral product lines, selling to South Korea, the Middle East, Europe, the United States and other regions.

I Peace Inc. is a Palo Alto, California-based biotech CDMO specializing in cGMP manufacturing of iPSC (induced pluripotent stem cells) and iPSC-derived cell products for cell and gene therapy development. The company provides custom GMP cell manufacturing, process development, cell banking (MCB/WCB), gene editing, differentiation services, and regulatory support compliant with FDA, PMDA, and EudraLex standards. I Peace has manufactured 100+ GMP iPS cell lines and tripled its CDMO facility capacity.